Immunotherapy for Gynecological Cancers

Intro
Five years Survival in Gynecologic Cancers 2005-2011
Chemotherapy Gynecologic Cancers
The Cancer-Immunity Cycle-Targeting Opportunities
Cancer and the Surrounding Tissue (Tumor Microenvironment)
The Cancer Cell Shield against Attack from the Immune System
Targeting the PD-L1/PD-1 Immune Checkpoint in Ovarian Cancer
Immune Check Point Inhibitors targeting PDL1 or PD1
Complete Response to Nivolumab in two Patients with Platinum Resistant Ovarian Cancer
Overall Best Response to Nivolumab in Patients with Platinum Resistant Ovarian Cancer
Effect of HPV targeted Tumor infiltrating T Cells on Cervical Cancer
Generation of Tumor Associated Antigen specific T Cells via Expression of TCR or CAR
CAR and TCR Cancer Clinical Trials in the US 1994 - 2014
Increase in Cell Persistence following lymphodepleting. preconditioning Chemotherapy prior to Adoptive Cell Transfer
Adoptive T Cell Therapy: Directing the Immune System against Ovarian Cancer Cells
Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients with Metastatic Synovial Ceil Sarcoma and Melanoma
Treatment of Patients with Metastatic Synovial Cell Sarcoma with Autologous T Cells Expressing TCRs Specific for NY-ESO-1
Immunotherapy Trials for Ovarian Cancer Stanford Gynecologic Oncology
The Clinical Research Group for Gynecologic Oncology Clinical Trials
Stanford Gynecologic Oncology Service Stanford Women's Cancer Center and Stanford Cancer Institute